The AMR Accelerator programme comprises 9 projects and has 98 participants operating in 18 countries.
Organisations such as universities, research institutes, EFPIA companies, and small and mid-sized companies across Europe, and beyond, collaborate in public-private partnerships, unified by a common goal of developing new tools and therapeutics to fight resistant pathogens, with a particular focus on targeting tuberculosis (TB) and Gram-negative infections.
Antimicrobial resistance knows no boundaries – neither should we!